SARS‐CoV‐2 PL<sup>pro</sup> Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment
The emergence of drug-resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID-19 pandemic. While de novo drug development is a time-consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS-CoV-2 papain-like protease inhibitor. This study extends those findings by investigating fidaxomicin's antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS-CoV-2, given its promising in vitro antiviral activity and favorable safety profile.
Authors
- Jelena Мilićević (ORCID: https://orcid.org/0000-0001-7783-6218)
- Milica Crnoglavac Popović (ORCID: https://orcid.org/0000-0002-4357-5512)
- Sara Protić
- Radivoje Prodanović (ORCID: https://orcid.org/0000-0003-4662-1825)
- Slobodan Paessler (ORCID: https://orcid.org/0000-0002-2213-9551)
- Milan Senćanski (ORCID: https://orcid.org/0000-0002-7296-3223)
- Kristina Stevanović (ORCID: https://orcid.org/0009-0002-7066-426X)
- Vladimir Perović (ORCID: https://orcid.org/0000-0002-3700-6452)
- Olivera Prodanović (ORCID: https://orcid.org/0000-0003-4460-5485)
- Sanja Glišić (ORCID: https://orcid.org/0000-0001-5691-1055)
- Nevena Kaličanin
Institutions
- University of Belgrade (RS)
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- ChemistryOpen
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1002/open.202400091
- Citations
- 5
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.81
Funders
- Science Fund of the Republic of Serbia